Molecular Tumor Board Recommendations for 69 Serous Ovarian Cancer Patients

Fabian B. T. Kraus published a dataset on figshare in May 2026 analyzing the real-world impact of molecular tumor boards (MTBs) in ovarian cancer. The dataset covers 69 patients with high-grade or low-grade serous ovarian cancer presented at the University Hospital LMU Munich MTB between November 2017 and June 2023. It includes assessments of molecular alterations, actionability, MTB recommendations, and clinical implementation.

Use Cases

• Analyze the frequency of actionable molecular alterations based on the reported 0.12 proportion in the cohort.
• Compare treatment recommendation implementation rates between HGSOC and LGSOC patient groups mentioned in the description.
• Study the relationship between patient clinical deterioration and non-implementation of MTB suggestions as described in the results.

Strengths

• Dataset includes 69 patient records with comprehensive molecular profiling.
• Provides a real-world cohort with a defined time range from November 2017 to June 2023.
• Reports specific metrics, such as a 0.36 proportion of actionable alterations in LGSOC patients.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small at 13.1 KB, indicating a limited scope.

Provenance

Source

University Hospital LMU Munich

Collection Method

Retrospective analysis of patients presented at an interdisciplinary molecular tumor board.

Time Range

November 2017 to June 2023

Freshness

Last updated 2026-05-19 05:29:13; freshness should be verified.